Get Plus

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

Ongoing Story· Day 4

Israeli Study Links Weight-Loss Drugs to Lower Dementia Risk

2 developments

CursorinfoHealth

Israeli Study Links Diabetes Drugs to Lower Dementia Risk

Translated & summarized from Cursorinfo by baba

CommunityNeutral tone

Russian · 1 newsroom

An Israeli study of nearly 47,000 patients found that popular GLP-1 diabetes and obesity drugs were associated with a 14% lower relative risk of developing dementia. The research, published in the European Journal of Internal Medicine, observed a stronger protective effect in women and older adults. However, scientists caution that the study is observational and does not prove causation, recommending further clinical trials.

The story in 6 lines · by baba

  • Israeli study links GLP-1 diabetes drugs to a 14% lower relative risk of dementia.
  • The research analyzed data from nearly 47,000 patients with type 2 diabetes and obesity.
  • A stronger protective association was observed in women and individuals aged 65 and older.
  • The findings were published in the European Journal of Internal Medicine.
  • Researchers caution that the study is observational and does not prove causation.
  • Further clinical trials are needed to confirm potential cognitive benefits.

An Israeli study involving nearly 47,000 patients suggests a link between popular GLP-1 class drugs, used for type 2 diabetes and obesity, and a reduced likelihood of developing dementia. Researchers from Israel analyzed several years of medical data, finding that outcomes varied based on the type of medication taken. The findings were published in the European Journal of Internal Medicine.

The study, which utilized electronic health records from the Israeli health fund "Clalit," compared patients initiating GLP-1 medications like semaglutide and liraglutide with those on other oral blood sugar-lowering drugs. The analysis included 46,962 individuals with type 2 diabetes and obesity who began treatment between 2008 and 2021. Over a median follow-up of seven years, dementia was diagnosed in 4.8% of patients taking GLP-1 drugs, compared to 7.8% of those on other medications.

After statistical adjustments, the use of GLP-1 drugs was associated with a 14% reduction in the relative risk of dementia. This association was more pronounced in women (22% reduction) and individuals aged 65 and older (18% reduction). However, the researchers stressed that these are observational findings and do not prove a causal relationship or guaranteed protective effect for specific groups.

Further analysis indicated that the protective association was statistically significant when compared to older diabetes drugs like sulfonylureas, but not when compared to DPP-4 or SGLT2 inhibitors. The study also examined the link with Parkinson's disease but found no statistically significant reduction in risk. The exact mechanism by which these drugs might influence brain health remains unclear, though potential factors include their impact on inflammation and brain cell metabolism.

The study authors emphasized that their research is observational and cannot establish causation. The results apply specifically to patients with type 2 diabetes and obesity, and individuals should not start or alter their medication based on these findings without consulting a doctor. Further clinical trials are needed to confirm any potential cognitive benefits.

CursorinfoOther · Tel Aviv

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

HealthTopic

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

Mentioned

Related stories · 1

Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.

Open the Wire